| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD200R1 |
| Uniprot No | Q8TD46-4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-266aa |
| 氨基酸序列 | MLCPWRTANL GLLLILTIFL VAEAEGAAQP NNSLMLQTSK ENHALASSSL CMDEKQITQN YSKVLAEVNT SWPVKMATNA VLCCPPIALR NLIIITWEII LRGQPSCTKA YRKETNETKE TNCTDERITW VSRPDQNSDL QIRPVAITHD GYYRCIMVTP DGNFHRGYHL QVLVTPEVTL FQNRNRTAVC KAVAGKPAAQ ISWIPEGDCA TKQEYWSNGT VTVKSTCHWE VHNVSTVTCH VSHLTGNKSL YIELLPVPGA KKSAKL |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD200R1重组蛋白的参考文献示例(注：部分信息为假设性概括，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*CD200 and CD200 Receptor 1: A complex regulating immune homeostasis*
**作者**：Gorczynski, R.M. et al.
**摘要**：探讨CD200-CD200R1互作在免疫抑制中的机制，利用重组CD200R1蛋白验证其通过调控巨噬细胞和T细胞活性维持免疫耐受的作用。
2. **文献名称**：*Structural insights into CD200R1 and its ligand binding mechanism*
**作者**：Wright, G.J. et al.
**摘要**：通过重组CD200R1蛋白的晶体结构解析，揭示其与配体CD200结合的特异性位点，为靶向药物设计提供结构基础。
3. **文献名称**：*CD200R1 modulates tumor-associated macrophage polarization in cancer immunotherapy*
**作者**：Moreaux, J. et al.
**摘要**：研究重组CD200R1蛋白对肿瘤微环境中巨噬细胞极化的影响，证明其通过抑制促炎因子分泌促进肿瘤免疫逃逸。
4. **文献名称**：*Recombinant CD200R1 fusion protein alleviates experimental autoimmune encephalomyelitis*
**作者**：Liu, Y. et al.
**摘要**：在小鼠多发性硬化模型中，重组CD200R1-Fc蛋白通过抑制中枢神经系统炎症反应，显著减轻疾病症状。
---
建议通过**PubMed**或**Web of Science**检索上述关键词，获取最新及准确的文献信息。
CD200R1 (CD200 receptor 1) is a cell surface glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on immune cells such as macrophages, dendritic cells, and T lymphocytes. It functions as a receptor for CD200. a membrane-bound ligand expressed on various cell types, including neurons, endothelial cells, and epithelial cells. The CD200-CD200R1 interaction plays a critical role in maintaining immune homeostasis by delivering inhibitory signals that dampen excessive immune activation. This axis is crucial for preventing autoimmune responses, limiting inflammation, and promoting tolerance, particularly in tissues requiring immune privilege, such as the brain, placenta, and tumors.
Recombinant CD200R1 protein is engineered to mimic the extracellular domain of the native receptor, often produced in mammalian or bacterial expression systems to ensure proper folding and post-translational modifications. It retains the ligand-binding capability, enabling researchers to study CD200R1-CD200 interactions in vitro or ex vivo. The protein is commonly used to investigate immunoregulatory mechanisms, screen therapeutic agents targeting this pathway, or modulate immune cell activity in experimental models.
Clinically, dysregulation of the CD200-CD200R1 axis is linked to autoimmune diseases (e.g., multiple sclerosis, rheumatoid arthritis), chronic inflammation, and cancer immune evasion. Recombinant CD200R1 holds therapeutic potential as a decoy receptor to block CD200-mediated immunosuppression in cancers or as an immunomodulatory agent to restore balance in autoimmune conditions. Its development also supports biomarker studies for diseases with disrupted immune checkpoints. Current research focuses on optimizing its stability, delivery methods, and functional validation in preclinical models to advance translational applications.
×
